| Next |
Ad
EPZM Message Board | Epizyme Inc.
home / stock / epzm / epzm message board
Message Board | Epizyme Inc. (NASDAQ:EPZM)
| Subject | By | Source | When |
|---|---|---|---|
| Expiration of the Offer (8/12/22) | Enterprising Investor | investorshub | 08/12/2022 1:31:51 PM |
| Thank | Pt3 | investorshub | 06/28/2022 1:52:48 AM |
| 1.45 + 1 = 2.45 Is what I | JJL | investorshub | 06/28/2022 1:47:18 AM |
| Jump in blindly what is this buyout 1.45 | Pt3 | investorshub | 06/27/2022 7:48:36 PM |
| Retrace | JJL | investorshub | 06/27/2022 4:38:33 PM |
| Ready for what | Pt3 | investorshub | 06/27/2022 4:18:53 PM |
| Nice! | JJL | investorshub | 06/27/2022 2:53:57 PM |
| I'm ready!! | JJL | investorshub | 06/27/2022 1:23:23 PM |
| $EPZM: See ya-all up on the MOON by | Invest-in-America | investorshub | 06/27/2022 1:18:29 PM |
| I have average of 0,59 | Vincent1974 | investorshub | 06/26/2022 11:14:04 AM |
| Am I the only one on ihub that | JJL | investorshub | 06/25/2022 12:13:58 AM |
| It hasn't stopped moving up for sure!!! | JJL | investorshub | 06/23/2022 2:13:34 AM |
| $EPZM Bottom channel breakout attempt. Increasing momentum. Increasing | SONARSTOCKZ | investorshub | 06/14/2022 4:10:35 PM |
| Yes I just go to figure a good | JJL | investorshub | 06/09/2022 2:28:29 AM |
| Primed and ready for a big run | Engle1488 | investorshub | 06/09/2022 2:27:00 AM |
| I completely agree! I loaded! | JJL | investorshub | 06/09/2022 2:10:36 AM |
| Looking very good last few sessions | Engle1488 | investorshub | 06/08/2022 8:21:35 PM |
| When the form fours stop this is going | JJL | investorshub | 06/03/2022 2:17:10 AM |
| I added. Good news! | JJL | investorshub | 06/03/2022 1:39:52 AM |
| Okay, so 7.50 support back then tells me | JJL | investorshub | 04/13/2022 12:52:27 AM |
Stock Information
Get EPZM Alerts
News, Short Squeeze, Breakout and More Instantly...
Epizyme Inc. Company Name:
EPZM Stock Symbol:
NASDAQ Market:
0.0% G/L:
$1.47 Last:
7,960 Volume:
$0 Open:
$1.47 Close:
Epizyme Inc. Website:
Ad
-
TAZVERIK® (tazemetostat) Net Product Revenue of $11.0 Million for 2Q 2022; Total End User Demand Grew 17% vs. 1Q 2022 First Patient Dosed in the SET-101 Phase 1/1b Study of EZM0414, the Company’s Novel, First-in-Class, Oral SETD2 Inhibitor Merger with I...
-
The biotech investment sector has always been its own market, very distinct from other sectors. So it was no surprise that when most sectors turned slowly upward after the pandemic-inspired crash, Biotech (XBI) rose 164%, exceeding the overall market (SPY) performance by triple digits. Then, a...
-
Shares of the commercial-stage cancer company Epizyme (NASDAQ: EPZM) are soaring today. Specifically, the drugmaker's stock is up by a handsome 58% as of 10:50 a.m. ET Monday. Epizyme's shares are racing higher today in response to a buyout agreement with French biopharma Ipse...